SHL Telemedicine receives CFDA – Chinese FDA approval for the smartheart TM

Tel Aviv/Zurich, 13 May 2014 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN), a leading provider and developer of advanced personal telemedicine solutions, announced that it has received the China Food and Drug Administration (“CFDA”) approval for the marketing of the smartheart TM in China. The smartheart TM has already received marketing approvals in Europe, the US and Japan
For more information click here